Vellore Typhoid Vaccine Impact Trial

Typhoid Fever Clinical Trial

— VEVACT  

Official title:

Vellore Typhoid Vaccine Impact Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05500482
• Other study ID #: 14247[INTERVEN]
• Status: Recruiting
• Phase: Phase 4
• Start date: May 1, 2023
• Est. completion date: December 31, 2025

Study information

• Verified date: September 2023
• Source: Christian Medical College, Vellore, India
• Contact: Jacob John, MD PhD
• Phone: 00919442631628
• Email: jebu[@]cmcvellore.ac.in
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This cluster randomised trial will examine the impact of introducing TyphiBEV, a typhoid conjugate vaccine licensed in India, on the incidence of typhoid fever in a high burden urban setting in South India.

Description:

TyphiBEV®, a typhoid conjugate vaccine from Biological E, has been licensed by the Central Drugs Standard Control Organaisation in India based on immunogenicity and safety data. A similar typhoid conjugate vaccine has been demonstrated in large clinical trials to provide 80% vaccine efficacy in Nepal and Bangladesh. The TyphiBEV® has not been similarly evaluated. The demonstration of the impact of a city-scale typhoid conjugate vaccine introduction on the burden of typhoid will aid policy decisions on the use of typhoid conjugate vaccines in the national immunisation program.

After written informed consent, the investigators will establish stimulated passive surveillance in 72,000 individuals between 1 and 30 years of age within the Vellore Demographic Surveillance System to determine the incidence of blood-culture confirmed typhoid fever. Thirty-six thousand surveillance participants between 1 year and 30 years residing in the 30 clusters (areas) randomised to receive the vaccine will receive the vaccine at the beginning of the trial. Those in other areas will receive the same at the end of two years. Using a stimulated passive surveillance approach, those with acute febrile illness will be encouraged to visit study surveillance hospitals. Participants will be evaluated for blood-culture confirmed typhoid fever if they are eligible. The incidence of typhoid among those living in areas assigned to vaccination compared to those whose residence is in areas not designated for vaccination will be used to calculate the impact of the vaccine on disease burden.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 72500
• Est. completion date: December 31, 2025
• Est. primary completion date: June 30, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 1 Year to 30 Years

Eligibility

Inclusion Criteria:

• Consent

• For adults, 18 years and over - they must be willing and competent to provide informed consent

• For those aged under 18 years, the parent/guardian is willing and competent to provide informed consent, and if the participant is 11 to 18 years of age, informed assent will also be sought,

• Age:

• Between 1 and 30 years (i.e., up to 29 years 364 days) at time of recruitment into the surveillance

• Currently living within the study catchment area with no plans to leave the study area in the next 24 months

Exclusion Criteria:

• For fever surveillance

o Medical reasons that prevent the participant from complying with study requirements including follow up and testing during illness

• For vaccination

• Has received a typhoid vaccine in the previous three years

• Is known to have an allergy to any vaccine component

• Nursing mothers, Pregnancy or planning pregnancy around vaccination

• Receipt of any other vaccine in the past 30 days (temporary exclusion)

• Febrile illness in the 24 hours before vaccination (temporary exclusion)

Related Conditions & MeSH terms

• Typhoid Fever

Intervention

Biological:
• Typhoid conjugate Vaccine
TyphiBEV is a clear colourless monovalent vaccine containing 25 µg of Typhoid Vi polysaccharide manufactured using the Citrobacter freundii sensu lato3056 (Vi) and is conjugated to CRM 197 as a carrier protein. Sodium chloride and Phosphate buffer are used as a buffering agent in the vaccine formulation with 2-Phenoxyethanol as a preservative.

Locations

Country	Name	City	State
India	Christian Medical College Vellore	Vellore	Tamil Nadu

Sponsors (4)

Lead Sponsor	Collaborator
Christian Medical College, Vellore, India	Bill and Melinda Gates Foundation, Imperial College London, University College, London

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Indirect effect	The number of blood culture confirmed typhoid fever episodes in unvaccinated participants from vaccine clusters compared to the number of blood culture confirmed typhoid fever episodes in unvaccinated participants from non-vaccine clusters	at 24 months of follow up beginning 28 days after vaccine introduction in vaccine clusters.
Other	Effect on hospitalised typhoid fever	The number of blood culture confirmed typhoid fever episodes in hospitalised participants who have been vaccinated compared to the number of blood culture confirmed typhoid fever episodes in hospitalised participants who have not been vaccinated	at 24 months of follow up beginning 28 days after vaccine introduction in vaccine clusters.
Primary	Total effect	Number of blood culture confirmed typhoid fever episodes in vaccinated participants from vaccine clusters compared to the number of blood culture confirmed typhoid fever episodes in unvaccinated participants from non-vaccine clusters	at 24 months of follow up beginning 28 days after vaccine introduction in vaccine clusters.
Secondary	Overall effect	The number of blood culture confirmed typhoid fever episodes in participants from vaccine clusters compared to the number of blood culture confirmed typhoid fever episodes in participants from non-vaccine clusters	at 24 months of follow up beginning 28 days after vaccine introduction in vaccine clusters.
Secondary	Effect in children 1 to 14 years	The number of blood culture confirmed typhoid fever episodes in vaccinated children between 1 year and 14 years and 364 days from vaccine clusters compared to the number of blood culture confirmed typhoid fever episodes in unvaccinated children between 1 year and 14 years and 364 days from non-vaccine clusters	at 24 months of follow up beginning 28 days after vaccine introduction in vaccine clusters.
Secondary	Effect on all febrile illness requiring healthcare visits	The number of febrile illness episodes where healthcare is sought among vaccinated participants from vaccine clusters compared to unvaccinated participants from non-vaccine clusters	at 24 months of follow up beginning 28 days after vaccine introduction in vaccine clusters.
Secondary	Safety outcomes	The number and description of solicited and non-solicited adverse events reported within the first seven days after vaccination in the safety subset of vaccine recipients	Seven days after vaccine receipt